Johnson & Johnson Pharmaceutical Services, L.L.C, Raritan, NJ, USA, 4 Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 5 United Biosource Corporation, Medford, MA, USA OBJECTIVE: Quantify the budgetary impact of adding a new carbapenem, doripenem, to a hospital formulary for treatment of complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) and nosocomial pneumonia (NP) including ventilator-associated pneumonia (VAP), in the United States. Doripenem has been approved in the US for cIAI and cUTI and is under FDA review for treatment of NP, including To quantify the workforce and cost implications of routine doctor-intensive (DI), nurse-intensive (NI) and pharmacist-intensive (PI) ART follow-up algorithms for HIV/ AIDS treatment at the Infectious Diseases Institute, a large urban HIV clinic in Kampala, Uganda. METHODS: We performed a societal perspective cost analysis including health resource utilization and opportunity cost of patient waiting (PW) time. A time-motion survey was performed to estimate median health worker utilization (HWU) and PW times for different services. Unique personnel requirements were identified to determine hourly HWU per patient, which was multiplied by hourly wages for different cadres. PW times were multiplied by mean hourly wage for Ugandans. National workforce and cost implications were projected. RESULTS: Median HWU and PW times per visit (hours) were 0.20 and 0.24 for triage nurses, 0.12 and 1.10 for doctors, 0.08 and 0.27 for pharmacists, and 0.13 and 0.05 for nurses. HWU time for refill pharmacists was 0.03 with no waiting. Hourly wages were: nurses-$4.6, doctors-$8.3, and pharmacists-$3.3. The average Ugandan hourly wage was $0.99. Total annual societal per-patient cost of follow-up was $45.2 for DI, $28.3 for NI and $16.3 for PI. Total projected national annual follow-up cost was $13.5 million for DI, $8.5 million for NI and $4.9 million for PI. Extrapolating to a national level, we project that the substitution of nurses or pharmacists for doctors would save 404 fulltime-equivalent doctors per year, 18.4% of the current number practicing in Uganda. CONCLUSION: The use of NI and PI innovations as substitutes for DI follow-up results in substantial reductions in doctor demand and substantial societal cost savings. Since prior research suggests no adverse impact on adherence to drugs and follow-up of these innovations, serious consideration should be given to policy changes to adopt substituting for doctor for routine HIV follow-up care. To evaluate all-cause mortality and cost of treatment in patients with refractory invasive aspergillosis (rIA) treated with either posaconazole or other systemic anti-fungal (SAF) therapies. METHODS: All-cause mortality and cost of salvage therapy of posaconazole oral suspension (800 mg/day) and other SAF treatments were assessed using a multicenter clinical study in patients with IA refractory to or intolerant of conventional antifungal therapy. Data from external controls were collected retrospectively providing a comparative reference group. All patients had failed to improve or progress with prior SAF therapies. Prior SAF treatments for the majority of patients were liposomal amphotericin B, amphotericin B, or itraconazole. Cases of aspergillosis deemed evaluable by a blinded data review committee included 107 posaconazole and 86 control subjects (modified intent-to-treat population). The populations were comparable regarding pre-specified demographic and clinical characteristics. All-cause mortality were analyzed using the survival technique. Economic evaluations were conducted using survival data and costs of pharmacotherapy one year post therapy (2007 Canadian dollars). RESULTS: Significantly more posaconazole-treated patients responded to therapy as compared with other SAF therapies. Patients with rIA treated with posaconazole appeared to confer a highly significant survival benefit over the control cases. The cumulative rates of survival at 30 days and at the end of therapy were 74% and 38%, respectively. For controls, those survival rates were 49% and 22%, respectively. The KaplanMeier survival curves were significantly different (P = 0.0003). In addition, posaconazole appeared to be a cost-saving option for the treatment of rIA compared with the active comparator receiving standard SAF treatments ($14,839 vs. $38,158) . Sensitivity analyses demonstrated the robustness of the results over a range of alternative values for costs and outcomes. CONCLUSION: Treatment with posaconazole compared with other SAF treatments provided a significant survival benefit in patients with rIA at lower cost of drug therapy.
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PIN11 COST SAVINGS FROM REDUCED HIV INCIDENCE ESTIMATES
Flavin JK, Becker RV Dymaxium Inc, Toronto, ON, Canada OBJECTIVE: The "AIDS epidemic update" (2007) published by the United Nations (UN) and World Health Organization (WHO), reports lower estimates of incidences of persons infected with HIV globally. This study evaluates the cost savings of these lower estimates on costs associated with patients being treated by antiretroviral (ARV) drugs and opportunistic infection (OI) prophylaxis. METHODS: Estimated differences in incidences of persons infected with HIV for the eight global regions in years 2006 and 2007 were calculated from UN reports. This difference was then multiplied by the average percentage of patients on ARV and OI treatment. Further, to derive the total cost savings associated with the ARV cohort, the number of patients on ARV medication was multiplied by a weighted average of first and second line ARV drug costs, lab costs, counseling costs, inpatient costs and outpatient costs, for each region. Conversely, only counseling and OI drug costs were included in the total cost of patients receiving OI prophylaxis treatment, for each region. Costs were reported in 2006 US dollars. Sensitivity analysis performed on all key parameters. RESULTS: The reduction of incidences of persons infected with HIV from 2006 to 2007 resulted in a total cost savings of $309.5 million, or 42%. Separately, the patients being treated by ARV drugs attributed a cost savings of $274.7 million, contrary to patients on OI drugs attributing $34.8 million to cost savings. The greatest savings were shown in the Sub-Saharan Africa region ($191.1 million). CONCLU-SION: Based on the revised estimates, the worldwide savings is a large percentage of the treatment budget. Notwithstanding increased incidence rates in subsequent years, these savings should continue beyond 2007.
